Peter M Vila1, Neel K Bhatt1, Randal C Paniello1. 1. Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St. Louis, St. Louis, Missouri, U.S.A.
Abstract
OBJECTIVE: To determine whether injection laryngoplasty within 6 months following the onset of unilateral vocal fold paralysis (UVFP) decreases the rate of permanent thyroplasty in adults. DATA SOURCES: Search strategies created by a medical librarian were implemented in multiple online research databases. REVIEW METHODS: Inclusion and exclusion criteria were designed to capture randomized clinical trials and cohort studies examining adults with UVFP who received injection laryngoplasty early in the course of treatment, within 6 months of onset, or who were observed. The primary outcome was the rate of thyroplasty. The Newcastle-Ottawa scale was used to assess quality of included cohort studies. Random effects meta-analysis was used to calculate an overall relative risk (RR). Heterogeneity was evaluated with the I2 statistic. RESULTS: The search strategy resulted in 1,177 studies, of which four cohort studies remained for meta-analysis after applying inclusion and exclusion criteria. All studies were rated as 9 of 9 on the Newcastle-Ottawa scale. Meta-analysis of 275 patients with UVFP revealed that the overall pooled RR of undergoing thyroplasty in those receiving an early injection was 0.25 (95% confidence interval 0.14-0.45) compared to conservative management (late or no injection). The I2 overall was 62.4%. CONCLUSION: Otolaryngologists should offer injection laryngoplasty to patients with a diagnosis of UVFP within 6 months of diagnosis (recommendation based on grade C evidence with a preponderance of benefit over harm). Laryngoscope, 128:935-940, 2018.
OBJECTIVE: To determine whether injection laryngoplasty within 6 months following the onset of unilateral vocal fold paralysis (UVFP) decreases the rate of permanent thyroplasty in adults. DATA SOURCES: Search strategies created by a medical librarian were implemented in multiple online research databases. REVIEW METHODS: Inclusion and exclusion criteria were designed to capture randomized clinical trials and cohort studies examining adults with UVFP who received injection laryngoplasty early in the course of treatment, within 6 months of onset, or who were observed. The primary outcome was the rate of thyroplasty. The Newcastle-Ottawa scale was used to assess quality of included cohort studies. Random effects meta-analysis was used to calculate an overall relative risk (RR). Heterogeneity was evaluated with the I2 statistic. RESULTS: The search strategy resulted in 1,177 studies, of which four cohort studies remained for meta-analysis after applying inclusion and exclusion criteria. All studies were rated as 9 of 9 on the Newcastle-Ottawa scale. Meta-analysis of 275 patients with UVFP revealed that the overall pooled RR of undergoing thyroplasty in those receiving an early injection was 0.25 (95% confidence interval 0.14-0.45) compared to conservative management (late or no injection). The I2 overall was 62.4%. CONCLUSION: Otolaryngologists should offer injection laryngoplasty to patients with a diagnosis of UVFP within 6 months of diagnosis (recommendation based on grade C evidence with a preponderance of benefit over harm). Laryngoscope, 128:935-940, 2018.
Authors: F Granato; F Martelli; L V Comini; P Luparello; S Coscarelli; O Le Seac; S Carucci; P Graziani; R Santoro; G Alderotti; M R Barillari; Giuditta Mannelli Journal: Eur Arch Otorhinolaryngol Date: 2019-08-02 Impact factor: 2.503
Authors: Chang Hwan Ryu; Seung Jin Lee; Jae-Gu Cho; Ik Joon Choi; Yoon Seok Choi; Yong Tae Hong; Soo Yeon Jung; Ji Won Kim; Doh Young Lee; Dong Kun Lee; GIljoon Lee; Sang Joon Lee; Young Chan Lee; Yong Sang Lee; Inn Chul Nam; Ki Nam Park; Young Min Park; Eui-Suk Sung; Hee Young Son; In Hyo Seo; Byung-Joo Lee; Jae-Yol Lim Journal: Clin Exp Otorhinolaryngol Date: 2021-06-01 Impact factor: 3.372